As a result of activating the inflammatory-immune system, pneumonia may trigger cardiovascular complications.
Patients undergoing evaluation for ventilator-associated pneumonia who had an alveolar neutrophil percentage 90% for bacterial pneumonia.
Increases in the relative rates of culture negative pneumonia that required hospitalization or emergency department visits were significantly associated with increased concentrations of fine particulate air pollution.
Treating severe community-acquired pneumonia with a combination of corticosteroids and antibiotics may be a cost-effective strategy.
Invasive pneumococcal disease was significantly higher in premature infants than in infants born at term.
A meta-analysis of case-control studies supports the use of the 13-valent pneumococcal conjugate vaccine in children as it protects against serotype 3.
Compared with idiopathic pulmonary fibrosis, nonhoneycomb hypersensitivity pneumonitis phenotypes are associated with greater improvements in percent-predicted forced vital capacity.
Patients with bacterial pneumonia are at higher risk for major adverse cardiovascular events within 90 days compared with patients with viral pneumonia.
Hands can be vehicles for transmission of pneumococcus and lead to acquisition of nasopharyngeal colonization.
The risk of having a healthcare-associated infection was 16% lower in 2015 than in 2011.
The CHEST Expert Cough Panel agreed on cough, dyspnea, pleural pain, sweating, shivers, aches, temperature of ≥38°C, tachypnea, and new and localizing chest examination signs as clinical symptoms as criteria suggestive of pneumonia in outpatient adults.
Survey finds variance in provider knowledge of adult pneumococcal vaccine recommendations.
Significant associations were seen between increased average prenatal carbon monoxide and reduced time to peak tidal expiratory flow to expiratory time, increased respiratory rate, and increased minute ventilation.
Antipseudomonal combination therapy has shown poorer efficacy than antipseudomonal monotherapy in individuals with suspected pseudomonal pneumonia.
The burden of childhood and infant pneumonia can be effectively reduced through the use of the pneumococcal Haemophilus influenzae protein D conjugate vaccine.
PCV13 in adults age <65 years with diabetes could reduce a substantial number of pneumonia hospitalizations.
The use of fluoroquinolones in stable patients with community-acquired pneumonia can be reduced with stewardship programs that share antibiotic use data and provide guidance for step-down therapy.
The FDA has approved Nuzyra for the treatment of adult patients with CABP and acute bacterial skin and skin structure infections.
For patients with CAP, antibiotic regimens including a fluoroquinolone may reduce mortality risk by 1-2% compared to beta-lactams and cephalosporins alone.
Previous antibiotic use and mechanical invasive ventilation were risk factors for multidrug-resistant pathogens in hospital-associated or ventilator-associated pneumonia.
Patients with community-acquired pneumonia who received corticosteroids had a lower incidence of myocardial infarction compared with those who did not.